Press Releases


IXICO to present at 10th Annual CNS Summit 2019

IXICO today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

Read more

IXICO participating at the CPAD 2019 Annual Meeting & Regulatory Science Workshop

Dr Robin Wolz, SVP of Science & Innovation at IXICO, will be attending the CPAD 2019 Annual Meeting & Regulatory Science Workshop on Oct 29 in Arlington, Virginia (USA).

Read more

IXICO announces client contracts and appointment of Chief Business Officer

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces three new biopharma contracts and the appointment of Lammert Albers as Chief Business Officer effective immediately.

Read more

Trading update for year ended 30 September 2019

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019.  IXICO is expecting its first full year of positive earnings before interest, tax, depreciation and amortisation ("EBITDA") since listing.

Read more

IXICO's Katherine Gray to present at the AMYPAD General Assembly Meeting

Dr Katherine Gray, Associate Director in Clinical Science at IXICO, will be presenting at the AMYPAD General Assembly Meeting (10-11 Oct) in Barcelona, Spain.   IXICO is currently collecting data for both the AMYPAD DPMS (eCRF and imaging data) and PNHS (imaging data) studies using our proprietary data management platform, TrialTrackerTM.

Read more

IXICO joins the CPP Consortium

To coincide with the 2019 International Congress of Parkinson’s Disease and Movement Disorders that is taking place this week in Nice, France, IXICO is delighted to announce that it has recently joined the ground-breaking Critical Path for Parkinson’s consortium.

Read more

IXICO provides an update on new and current contracts

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an update on contracts:  ·   Two new biopharmaceutical client contracts with combined value of over £1m ·   Award of a significant change order to Phase III Huntington's disease contract worth c£0.

Read more

57-63 of 63 results